Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
- Govt Task Force Briefs Trade Groups on Tokyo’s Hosting of TPP Interim Talks on IP
October 23, 2013
- Basic Policy Calls for Wider Range of Uninsured Healthcare Services in National Strategic Special Zones
October 23, 2013
- Expert Panel Calls for Measures to Promote Commercialization of Results of Basic Research in Field of Healthcare
October 23, 2013
- DPJ Nagatsuma Requests Summoning Novartis President and Former Employee for Unsworn Diet Testimony
October 22, 2013
- Avastin to Receive Additional Indication for Ovarian Cancer: PAFSC’s Second Committee on Drugs
October 22, 2013
- Vaccine Policy Committee Agrees on Draft of Basic Vaccination Plan
October 22, 2013
- 72 Face-to-Face Consultations Provided from July 2011 through September 2013: PMDA
October 21, 2013
- Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
- CSIMC’s Bill Payer, Industry Reps at Odds over Objective of Premium; “Elimination of Drug Lag” vs. “New Drug Development”
October 18, 2013
- 1st Committee on Drugs to Discuss Approval for JT’s Hyperphosphatemia Treatment on October 28
October 18, 2013
- 60% of Products/Indications in 1st Round of Development Requests Approved as of June: MHLW
October 18, 2013
- CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation
October 17, 2013
- CSIMC to Study Introduction of Medical Fee for DPC Hospitals with High Generic Drug Use Rates in Fee-for-Service System
October 17, 2013
- PMDA to Kick Off Pilot Program for Electronic Filings of NDA Data in October
October 16, 2013
- Japan “Hopes to Find Common Ground” in Upcoming TPP Talks on Intellectual Properties: Minister Amari
October 16, 2013
- Generic-Name Prescribing Promoted Use of Generic Drugs in FY2012: CSIMC Committee
October 11, 2013
- CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar
October 10, 2013
- Expert Group Calls for Handling of Switch OTC Drugs as Careful as Ethical Drugs in Early Stage after Switching
October 10, 2013
- Working Group Finalizes Recommendation on Rules for Online Sales of OTC Drugs
October 10, 2013
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…